His daughter is 25, already on statins, and inherited the risk.
Among the eight million Canadians quietly carrying a genetic cholesterol marker called Lipoprotein(a), most will never know until something goes wrong — because the standard tests their doctors order simply don't look for it. New guidelines from the Canadian Lp(a) Working Group are asking family physicians to close that gap, urging them to screen for a particle that raises heart attack and stroke risk two to four times above average. The story of one man's near-fatal heart attack at 45, and his 25-year-old daughter already on medication for the same inherited risk, illustrates what is lost when a covered, accessible blood test remains invisible to those who need it most.
- A genetic cholesterol marker affecting one in five Canadians is being routinely missed because it doesn't appear on standard blood panels — leaving millions unaware they face two to four times the normal risk of heart attack or stroke.
- Darren Ali's widowmaker heart attack at 45 was the first sign he had ever received that something was wrong, and his daughter's test results — higher than his own at the time of his attack — show how silently the risk passes through families.
- New Canadian guidelines published this month are pushing family doctors to recognize Lp(a) as a priority screening target, aligning with similar guidance just released by the American College of Cardiology.
- The blood test is already covered by every provincial health plan, yet patients must specifically request it — a bureaucratic gap that specialists say is costing lives that early intervention could save.
- No drug yet exists to directly lower Lp(a), but several trials are underway, and in the meantime high-risk patients are being placed on statins to partially offset the danger while the medical community races to catch up.
Darren Ali was 45 and considered himself healthy when a vague pain in his upper back preceded a massive heart attack — the kind cardiologists call a widowmaker. He survived, but only afterward did he learn that his blood had carried a silent genetic threat his entire life, one that routine screening had never once flagged.
That threat is Lipoprotein(a), or Lp(a): a particle combining fat and protein that, in elevated concentrations, clings to blood vessel walls, builds plaques, promotes clotting, and raises the risk of heart attack or stroke two to four times above average. Roughly one in five Canadians — about eight million people — carry elevated levels. Most have no idea, because the standard cholesterol panel ordered at annual checkups doesn't test for it.
New guidelines published this month in the Canadian Journal of Cardiology, authored by the Canadian Lp(a) Working Group, are aimed at changing that. Directed at family physicians, the document outlines risk thresholds and clinical steps, and builds on earlier calls for one-time universal screening of all Canadian adults — a position now shared by the American College of Cardiology. Dr. Sonia Anand of McMaster University, one of the guidelines' authors, describes Lp(a) as among the most important things that can be measured in a routine blood draw for preventing cardiovascular death.
Because Lp(a) is almost entirely determined by genetics, it doesn't respond to diet or exercise and remains largely stable across a lifetime. Family history is therefore a critical signal. Dr. Alykhan Abdulla, a family physician in Ontario, notes that a close relative with high Lp(a) is reason enough to get tested, and that a range of other conditions — from existing heart disease to kidney problems — should prompt physicians to investigate. People of African, Caribbean, or South Asian descent face statistically higher rates of elevated levels.
No medication yet directly lowers Lp(a), though several trials are underway. For now, high-risk patients are typically prescribed statins to partially offset the danger. The test itself is covered by every provincial health plan — patients simply have to ask for it, and most don't know to.
Ali, now 52 and enrolled in a drug trial, no longer sees the stakes as abstract. His youngest daughter recently tested for Lp(a); her levels came back higher than his were at the time of his heart attack. She is 25 and already on statins. His message is direct: one blood test, no out-of-pocket cost, and the potential to change the course of a life — or a child's. The question is whether Canada's health system will make that test easy to find before the warning arrives in the form of a crisis.
Darren Ali was 45, healthy by most measures, when he noticed some unusual pain in his upper back. Three months later, he was having a massive heart attack — the kind doctors call a widowmaker. He describes the sensation as something like an elastic band cinching tight inside his chest. He survived. What he didn't know until afterward was that his blood had been carrying a quiet genetic threat his whole life, one that no standard test had ever looked for.
That threat has a name: Lipoprotein(a), or Lp(a). It's a particle that everyone carries in their bloodstream, part fat and part protein, but in elevated concentrations it becomes dangerous in ways that ordinary cholesterol tests don't capture. Lp(a) is stickier than other cholesterol types, which means it clings more readily to the walls of blood vessels. Over time, that buildup forms plaques. Plaques restrict blood flow. They can rupture. And Lp(a) also promotes clotting and inflammation, compounding the risk further. For someone with high levels, the chance of a heart attack or stroke is two to four times greater than for someone without.
Roughly one in five Canadians — about eight million people — carry elevated Lp(a) levels. Most of them have no idea. There are no symptoms. The standard cholesterol panel that millions of Canadians get at their annual checkup doesn't test for it. And until recently, awareness among family physicians has been inconsistent at best.
That's what a new set of guidelines, published this month in the Canadian Journal of Cardiology by the Canadian Lp(a) Working Group, is trying to change. The updated guidance is aimed squarely at family doctors, walking them through the risks, the thresholds, and the steps they can take when a patient tests high. It builds on earlier recommendations calling for one-time universal screening of all Canadian adults — a position now echoed by the American College of Cardiology, which released similar guidance last month. According to the updated document, a level of 100 nanomoles per litre or above signals elevated risk; 190 nanomoles per litre or above signals even greater danger.
Dr. Sonia Anand, a professor of medicine and epidemiology at McMaster University in Hamilton and one of the authors of the new guidance, puts it plainly: among all the things that can be measured in a blood draw, Lp(a) ranks among the most important for preventing one of the leading causes of death in Canada. The test itself is already covered by every provincial health plan. Patients simply have to ask for it — and most don't know to.
Because Lp(a) levels are almost entirely set by genetics, they don't respond to diet or exercise the way other cholesterol markers do. They're largely fixed from birth and stay stable across a lifetime, with some exceptions — levels tend to rise during pregnancy and after menopause. That genetic anchor means family history is a critical signal. Dr. Alykhan Abdulla, a family physician in Manotick, Ontario, says that if a close relative has high Lp(a), that alone is reason enough to get tested. He also flags a cluster of other conditions — existing heart disease, stroke, dementia, kidney problems, obesity, fatty liver, and erectile dysfunction — as prompts for physicians to investigate further. Research also shows that people of African, Caribbean, or South Asian descent face higher rates of elevated levels.
Treatment options remain limited. There is currently no medication that directly lowers Lp(a), though several clinical trials are underway. For now, patients diagnosed with high levels are typically prescribed statins — drugs that target a different form of bad cholesterol, LDL, to partially offset the cardiovascular risk that elevated Lp(a) creates. Dr. Jodi Heshka, a cardiometabolic specialist at the Ottawa Heart Institute, says she would support making Lp(a) testing a standard part of routine bloodwork, and she encourages patients to bring it up with their doctors themselves.
For Ali, now 52 and enrolled in a drug trial, the stakes are no longer abstract. His youngest daughter recently had her Lp(a) levels checked. They came back higher than his were at the time of his heart attack. She is 25 years old and already on statins. Ali's message is simple: it takes one blood test, it costs nothing out of pocket, and it could tell you something that changes the course of your life — or your child's. The question now is whether Canada's health system will make that test easy to find, or leave millions of people waiting for a warning sign that may never come.
Citações Notáveis
When we consider all of the potential things to be measured, this is a very important one to prevent one of the most common causes of death amongst Canadians.— Dr. Sonia Anand, McMaster University, co-author of the updated guidance
My youngest daughter has a lipoprotein(a) level higher than I did when I had my heart attack — she's already on statins and she's only 25. It just takes a simple blood test.— Darren Ali, heart attack survivor, Maple Ridge, B.C.
A Conversa do Hearth Outra perspectiva sobre a história
Why hasn't this been part of routine screening already if it affects one in five Canadians?
Partly inertia, partly the fact that there's no drug that directly fixes it — which makes some doctors wonder what the point of knowing is.
But knowing still matters even without a targeted treatment?
Absolutely. You can manage the surrounding risk factors more aggressively, watch for early warning signs, and get into trials for drugs that are coming.
What makes Lp(a) different from the cholesterol numbers most people already know?
It doesn't respond to lifestyle changes the way LDL does. You can't diet or exercise your way out of it. It's written into your genes.
So if your parent has it, you likely have it too?
That's exactly the logic. Ali's daughter inherited levels even higher than his. She's 25 and already on statins because of it.
The test is covered by every province — so what's actually stopping people from getting it?
They don't know to ask, and their doctors may not think to offer it. That's the gap these new guidelines are trying to close.
Is there any hope on the treatment side?
Several drug trials are running right now specifically targeting Lp(a). Ali himself is in one. The science is moving, just not there yet.
What's the single thing a person reading this should do tomorrow?
Call their doctor and ask for an Lp(a) blood test by name. That's it. One conversation, one draw, and you know where you stand.